{"id":"live-attenuated-hav-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108939","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a genetically weakened strain of hepatitis A virus that replicates in the body but does not cause clinical hepatitis. This replication triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against wild-type hepatitis A infection. The attenuated virus is sufficiently weakened to be safe while maintaining immunogenicity.","oneSentence":"This vaccine contains live attenuated (weakened) hepatitis A virus that stimulates the immune system to produce antibodies and cellular immunity against hepatitis A without causing disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:08.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in susceptible individuals"}]},"trialDetails":[{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07032610","phase":"","title":"Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents","status":"NOT_YET_RECRUITING","sponsor":"Chiang Mai University","startDate":"2025-06-22","conditions":"Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases","enrollment":60},{"nctId":"NCT06978621","phase":"PHASE3","title":"Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV","status":"RECRUITING","sponsor":"Chiang Mai University","startDate":"2025-05-25","conditions":"Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases","enrollment":36},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT06460545","phase":"PHASE4","title":"Phase IV Study of Concomitant Administration of the sIPV and HepA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-06-15","conditions":"Polio, Hepatitis A","enrollment":2000},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT01949857","phase":"PHASE4","title":"The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2013-09","conditions":"Hepatitis A","enrollment":35000},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT01198769","phase":"PHASE4","title":"Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-11","conditions":"Infections, Rotavirus","enrollment":15},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT03231605","phase":"PHASE4","title":"Comparative Immunogenicity Study of Two Hepatitis A Vaccines","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2017-07-26","conditions":"Hepatitis A","enrollment":300},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":"Encephalitis","enrollment":50},{"nctId":"NCT02601040","phase":"PHASE4","title":"Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2011-11","conditions":"Hepatitis A","enrollment":13500},{"nctId":"NCT01865968","phase":"PHASE4","title":"Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2008-10","conditions":"Hepatitis A","enrollment":239},{"nctId":"NCT01064141","phase":"PHASE2","title":"A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":210},{"nctId":"NCT00926419","phase":"PHASE2, PHASE3","title":"Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2009-06","conditions":"Varicella, Hepatitis A","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Live attenuated hepatitis A vaccines"],"phase":"marketed","status":"active","brandName":"Live attenuated HAV vaccine","genericName":"Live attenuated HAV vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine contains live attenuated (weakened) hepatitis A virus that stimulates the immune system to produce antibodies and cellular immunity against hepatitis A without causing disease. Used for Prevention of hepatitis A infection in susceptible individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}